Form 4: Akero Therapeutics CSO Exercises Stock Options
Insider Transaction Report
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised a significant number of stock options, acquiring 152,678 shares of common stock.
Summary
- Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc. (AKRO), reported multiple transactions on November 25, 2025.
- Rolph exercised stock options to acquire a total of 152,678 shares of common stock.
- The exercise prices for these options varied, including $28.35, $6.364, $21.09, $0.615, and $21.1 per share.
- Following these transactions, Rolph's direct beneficial ownership of common stock increased to 282,149 shares.
- All exercised options were vested and currently exercisable.
Sentiment
Score: 7
Explanation: The Chief Scientific Officer exercised a substantial number of stock options, increasing direct ownership in the company, which can be viewed as a positive signal of confidence.
Positives
- Chief Scientific Officer Timothy Rolph increased his direct beneficial ownership by 152,678 shares through option exercises, potentially signaling confidence in the company's future.
Future Outlook
This Form 4 filing primarily reports insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.
Industry Context
Insider transactions, such as the exercise of stock options, are a routine part of executive compensation and equity management within publicly traded companies. This activity by a Chief Scientific Officer is a standard event in the biotechnology and pharmaceutical industry, where equity incentives are common.
Related Party Transactions
- Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, Inc., exercised stock options to acquire common stock from the company. This is a direct transaction between an insider and the company.
Stakeholder Impact
- Shareholders: May view the increase in insider ownership as a positive signal of management's confidence in the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 11/25/2025 | Date of transaction (stock option exercises and acquisition of common stock) |
| 07/29/2028 | Expiration date for stock options to buy 2,796 shares at $0.615 |
| 10/17/2028 | Expiration date for stock options to buy 94,268 shares at $0.615 |
| 12/12/2029 | Expiration date for stock options to buy 43,064 shares at $6.364 and 4,284 shares at $21.09 |
| 12/07/2030 | Expiration date for stock options to buy 3,527 shares at $28.35 |
| 12/07/2031 | Expiration date for stock options to buy 4,739 shares at $21.1 |
Keywords
Akero Therapeutics, AKRO, Timothy Rolph, Chief Scientific Officer, Stock Options, Insider Trading, Form 4, Equity Acquisition, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.